Has Hayder Hashim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $824,274 in general payments to Hayder Hashim, MD across 1,356 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hayder Hashim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hayder Hashim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hayder Hashim, MD

Cardiovascular Disease · Washington, DCNPI 1104069442

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Abbott at 40.7% of the total. 2025 is the largest year on record at $253,518, more than ten times the $8,442 reported in 2019. Among cardiovascular disease clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$824,274in general payments, 2019–2025

Across 1,356 payments — averaging $607.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$336K
Boston Scientific$251K
Chiesi USA, Inc.$46K
Cardiovascular Systems Inc.$37K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$35K
Medtronic$31K
plus $87K from 29 others

$164,266in research payments, 2019–2025

Across 19 payments — averaging $8645.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Shockwave Medical, Inc$126K
Philips North America LLC$22K
Medtronic$17K

What the payments were for

Consulting fees$278,17034%
Speaking & faculty fees$416,19850%
Grants$1350%
Travel & lodging$93,63311%
Food & beverage$36,0274%
Education$900%
Gifts$210%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	424	$335,817
Boston Scientific	287	$250,994
Chiesi USA, Inc.	46	$46,389
Cardiovascular Systems Inc.	156	$37,232
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	57	$35,451
Medtronic	77	$30,912
Cordis US CORP.	13	$25,697
Philips North America LLC	33	$25,543
Penumbra, Inc.	23	$18,410
Terumo Medical Corporation	17	$9,630
Abiomed	29	$1,738
Amgen	35	$1,106
AstraZeneca	43	$902
Teleflex LLC	13	$771
Asahi Intecc USA, Inc.	5	$433
Acist Medical Systems, Inc.	1	$346
Novo Nordisk	15	$323
E.r. Squibb & Sons, L.L.C.	11	$300
Pfizer	17	$297
Cook Medical LLC	6	$278
Biotronik Inc.	3	$240
Shockwave Medical, Inc	13	$207
Johnson & Johnson	11	$207
ZOLL Circulation Inc	2	$198
Opsens Inc.	1	$157
Novartis	6	$145
W. L. Gore & Associates, Inc.	1	$117
Inari Medical, Inc.	1	$115
Siemens Medical Solutions USA, Inc.	2	$111
Celonova Biosciences, Inc.	1	$49
Atricure, Inc.	2	$42
Recor Medical Inc	2	$37
Cardiva Medical, Inc.	1	$29
Kestra Medical Technology Services, Inc.	1	$27
Boehringer Ingelheim	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$824,274 in reported general payments places this provider in the 95th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$214,326

Medicare patients

447

Services billed

912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	117	$725

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Washington

Joshua YamamotoWashington$376K
Mardi Gomberg-MaitlandWashington$320K
Jaffar KhanWashington$318K
Isaac Opoku-AsareWashington$146K
Judith HsiaWashington$65K
Ana BaracWashington$34K
Jonathan PlehnWashington$32K
Andrew ChoiWashington$32K
Felton AndersonWashington$23K
Jose VargasWashington$20K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →